

L13 ANSWER 12 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1993:813 CAPLUS  
 DOCUMENT NUMBER: 118:813  
 TITLE: antithrombotic peptides  
 INVENTOR(S): Maraganore, John M.; Jablonski, Jo Ann M.; Bourdon, Paul R.  
 PATENT ASSIGNEE(S): Biogen, Inc., USA  
 SOURCE: PCT Int. Appl., 47 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9213952	A1	19920820	WO 1992-US836	19920203 <--
W: AU, CA, FI, HU, JP, KR, NO				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
US 5240913	A	19930831	US 1991-652929	19910208 <--
AU 9213621	A1	19920907	AU 1992-13621	19920203 <--
AU 659828	B2	19950601		
EP 529031	A1	19930303	EP 1992-905748	19920203 <--
EP 529031	B1	20000524		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
JP 05506252	T2	19930916	JP 1992-505745	19920203 <--
HU 65675	A2	19940728	HU 1992-3500	19920203 <--
HU 218831	B	20001228		
AT 193325	E	20000615	AT 1992-905748	19920203 <--
ES 2149170	T3	20001101	ES 1992-905748	19920203 <--
CA 2079778	C	20020903	CA 1992-2079778	19920203 <--
US 5425936	A	19950620	US 1992-924549	19920731 <--
NO 9203889	A	19921208	NO 1992-3889	19921007 <--
NO 315710	B1	20031013		
US 5514409	A	19960507	US 1995-431678	19950502 <--
HK 1005995	A1	20010202	HK 1998-105075	19980609 <--
GR 3034257	T3	20001229	GR 2000-401944	20000824 <--
FI 2005000027	A	20050111	FI 2005-27	20050111
PRIORITY APPLN. INFO.:			US 1991-652929	A 19910208
			US 1989-395482	B2 19890818
			US 1990-549388	A2 19900706
			WO 1992-US836	A 19920203
			US 1992-924549	A3 19920731

OTHER SOURCE(S): MARPAT 118:813

AB Biol. active mols. are disclosed which bind to and inhibit thrombin. These mols. comprise a catalytic site-directed moiety XR2(R1)R3R4R5R6Y (X = H, backbone chain of 1-100 atoms; R1 = unsubstituted or mono- or di- or trisubstituted saturated ring; R2 = bond, 1-5 atom backbone chain; R3 = bond, 1-3 atom backbone chain; R4 = amino acid; R5 = L-amino acid which comprises guanidinium- or amino-containing side chain; R6 = nonamide bond; Y = 1-9 atom backbone chain) or XR2(R1')R3R4'R5R6Y (R1' = unsubstituted or mono- or di- or trisubstituted ring; R4' = amino acid comprising a side chain with a capacity to accept an H bond at pH 5.5-9.5; X, R2, R3, R5, R6, Y as above). Preferred thrombin inhibitors are characterized by an anion binding exosite associating domain (ABEAM) and a linker portion of 18-42Å in length which connects Y to the ABEAM. Also disclosed are compns., combinations, and methods which employ these mols. for therapeutic, prophylactic, and diagnostic purposes. Hirulog-8 [H-(D-Phe)-Pro-Arg-Pro-(Gly)4-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-OH] (I) was synthesized with standard solid-phase synthesis methodol. The X-ray crystallog. structure of the I-thrombin complex was obtained and used to design I analogs. In addition to showing enhanced antithrombin activity in vitro over I, D-cyclohexylalanyl-I also

showed a significantly increased anticoagulant effect in plasma assays over I.